Valeant Pharma (VRX) Issues Encouraging Update on Prelim. Phase II STAND Results
Valeant Pharma (NYSE: VRX) announced the presentation of new long-term, preliminary results from the Phase II STAND trial demonstrating a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)